Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now. There’s been huge hype around AI’s potential for drug discovery. But at Eli Lilly, ...

Eli Lilly is a market darling at the moment because of its industry-leading GLP-1 drugs. The stock looks priced for perfection despite a well-known drug cycle. That's good news, but investors are well ...

Elaine Carol Farley went home to be with the Lord on Monday, February 9, 2026. She was the youngest daughter of Carol (Neumann) Farley and Eugene “Whistle” Farley. A celebration of Elaine’s life will ...

Eli Lilly (NYSE: LLY) wasn't the first to market with a GLP-1 drug. However, its Mounjaro (for diabetes) and Zepbound (for weight loss) drugs have proven more effective than competing products. That's ...

A common refrain since GLP-1 weight-loss drugs hit the market is that the price of treatments has led many employers to hesitate about providing access to the drugs through company health plans. In ...

Eli Lilly & Co will invest $3 billion in China over the next decade to expand local production, with a focus on weight loss as the US drugmaker looks to cement its dominance in the booming obesity ...

Eli Lilly stock is down 13% from its 52-week high. Analysts still see some decent upside for the stock, with its average price target being north of $1,200. The company experienced tremendous growth ...

SHANGHAI, March 11 (Reuters) - Eli Lilly (LLY.N), opens new tab plans to invest $3 billion in China over the next decade, which will help build production capacity for its experimental ‌type-2 ...

Hims & Hers Health (HIMS) has made a major change in its PR function with the hiring of Kathryn Beiser, who has served Lilly (LLY) as the weight loss drugmaker’s chief communications officer for five ...

Add Yahoo as a preferred source to see more of our stories on Google. A screen displays the logo and trading information for Eli Lilly and Company on the floor at the New York Stock Exchange (NYSE) in ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...